Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France.
about
Prevalence and impact of minority variant drug resistance mutations in primary HIV-1 infectionRecent HIV-1 infection contributes to the viral diffusion over the French territory with a recent increasing frequencyHIV-1 subtype F1 epidemiological networks among Italian heterosexual males are associated with introduction events from South AmericaUse of sequence data generated in the Bayer Tru Gene genotyping assay to recognize and characterize non-subtype-b human immunodeficiency virus type 1 strainsImpact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected childrClinically relevant genotype interpretation of resistance to didanosineBurden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysisSexually-transmitted/founder HIV-1 cannot be directly predicted from plasma or PBMC-derived viral quasispecies in the transmitting partner.High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens.HIV drug-resistant strains as epidemiologic sentinelsHIV-1 protease and reverse transcriptase mutations for drug resistance surveillance.New and old complex recombinant HIV-1 strains among patients with primary infection in 1996-2006 in France: the French ANRS CO06 primo cohort study.Increase in hepatitis C virus incidence in HIV-1-infected patients followed up since primary infection.Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach.Spatiotemporal dynamics of HIV-1 transmission in France (1999-2014) and impact of targeted prevention strategies.Long-term follow-up of 11 protease inhibitor (PI)-naïve and PI-treated HIV-infected patients harbouring virus with insertions in the HIV-1 protease gene.Heterogeneity and penetration of HIV-1 non-subtype B viruses in an Italian province: public health implications.Resistance and virological response analyses in a three initial treatment strategy trial: a substudy of the INITIO trial.Human immunodeficiency virus-1 subtypes and antiretroviral drug resistance profiles among drug-naïve Brazilian blood donors.Characteristics of HIV-1 non-B subtype infections in Northwest Poland.Drug-resistance mutations in antiretroviral-naïve patients with established HIV-1 infection in Mexico.Recent changes in the management of primary HIV-1 infection: results from the French PRIMO cohort.Development and evaluation of a national reference panel of HIV-1 protease and reverse transcriptase drug-resistance mutations for HIV-1 genotypic resistance assays in China.Kommerzielle Systeme zur Genotypisierung von humanen Immundefizienzviren Typ 1: Vergleich von ViroSeq (Abbott) und TruGene (Bayer). Commercially available assays for genotyping of human immunodeficiency virus type 1: Comparison of ViroSeq (Abbott) anDM-PhyClus: a Bayesian phylogenetic algorithm for infectious disease transmission cluster inferenceHIV-1 nonsubtype B distribution across certain resource-rich countriesTwo-Months-off, Four-Months-on Antiretroviral Regimen Increases the Risk of Resistance, Compared with Continuous Therapy: A Randomized Trial Involving West African Adults
P2860
Q28478459-7CA23A03-7C38-42DE-8895-95D5B06BA90DQ28480667-2DAD1673-6E3C-4B16-A19D-3E303B1A3104Q28481828-7B4699C9-7018-439B-A53A-BD5EB64611A3Q31009699-8DBCE1CC-3CF2-4BB5-A502-28D47BEF4A63Q33267065-63F110CC-DD0C-405E-B8DA-1D940A4B63D0Q33770146-FBECB6DD-2BD3-48EF-B398-6B7E1EEBA9F1Q33988153-BE5C1DCA-99A0-4C97-BD38-AEAFFC4EBFB9Q34853144-9D7C94C7-EACD-4A36-81AF-E1E976351655Q35215399-A76245E5-0018-4418-B218-C51AAD8144BAQ36026355-BDB7D685-9860-4E21-AD82-130E98599D95Q36696351-D780BB32-805F-40B7-B009-64865405476AQ36908998-92C6A297-6150-4CBD-9F95-4CEB81DD465CQ36928649-6C96896A-B96C-4FAD-BE1D-20F441717E2CQ37189622-D62156CB-5303-40A3-BD35-BCAF41239B5CQ37278724-0250F768-AED2-4DD9-9B7B-8F919498DA98Q37661745-3365EE84-40D4-4289-847C-DE433BB6430CQ38415156-10A03FC8-B2C0-475D-9CBD-3C3037FBD8D0Q39530471-19C588AD-E37A-4A24-884A-75BFB9F992B2Q43172779-8931E3EE-F247-4F72-9707-17385FA518E2Q45408530-F32115F3-377C-4119-BB15-02DEA6FF4EEDQ46521546-84F7B713-E6C3-4A4A-809C-0176FA5AF556Q46789888-10E60F98-9643-4BF3-80F4-9FC0BF8C808FQ53885344-3C1DF00B-2FF1-4ECD-B9EE-F81E6E3955EEQ54695288-9DFED2A7-5BB9-458F-B9D2-93186DE0B269Q57083225-60A5B712-BEFA-45D0-B138-E8B6101E013EQ57157111-90529A5F-FF3E-4998-957F-3EB592B70EB7Q58485636-592EFBF6-7EF1-4B98-B061-93F0DB9B3F8BQ58827996-AE0FE7E9-51E9-49D9-BDE0-9473AB70183F
P2860
Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Stable prevalence of genotypic ...... ary HIV-1 infection in France.
@en
Stable prevalence of genotypic ...... ary HIV-1 infection in France.
@nl
type
label
Stable prevalence of genotypic ...... ary HIV-1 infection in France.
@en
Stable prevalence of genotypic ...... ary HIV-1 infection in France.
@nl
prefLabel
Stable prevalence of genotypic ...... ary HIV-1 infection in France.
@en
Stable prevalence of genotypic ...... ary HIV-1 infection in France.
@nl
P2093
P50
P1433
P1476
Stable prevalence of genotypic ...... ary HIV-1 infection in France.
@en
P2093
Annick Ruffault
Bernard Masquelier
Catherine Tamalet
Christiane Deveau
Françoise Brun-Vezinet
Isabelle Pellegrin
Laurence Meyer
Marie-Laure Chaix
Martine Harzic
Véronique Schneider
P304
P356
10.1097/00002030-200312050-00011
P407
P577
2003-12-01T00:00:00Z